Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 4/20 | 0.63 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | TP53 | P04637 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | PDE5A | O76074 | 1/20 | 0.54 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5550427 | 0.85 | PYGM (0.62) | PYGMDRD2TBXA2RMAPTTP53 | |
| SCHEMBL14470780 | 0.83 | PYGM (0.69) | PYGMDRD2TBXA2RKDM4EL3MBTL1 | |
| SCHEMBL5547114 | 0.81 | PYGM (0.60) | PYGMMAPTTP53HPGDKDM4E | |
| SCHEMBL5545682 | 0.79 | PYGM (0.78) | PYGMMAPTTP53KDM4EMEN1 | |
| SCHEMBL5550432 | 0.78 | PYGM (0.78) | PYGMMAPTTP53KDM4E | |
| SCHEMBL5550231 | 0.78 | PYGM (1.00) | PYGMMAPTTP53HPGDKDM4E | |
| SCHEMBL28402717 | 0.78 | MAPK1 (0.72) | MAPTTP53HPGDKDM4EALDH1A1 | |
| SCHEMBL28596201 | 0.77 | DRD2 (0.71) | DRD2TBXA2RMAPTTP53HPGD | |
| SCHEMBL9107840 | 0.75 | DRD2 (0.69) | DRD2TBXA2RMAPTTP53HPGD | |
| Ataquimast SCHEMBL1150373 | 0.75 | KDM4E (0.65) | PYGMMAPTTP53HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1711184-B1 | (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1711184-B1 | (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1711184-A1 | (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005067932-A1 | (3-OXO-3, 4-DIHYDRO-QUINOXALIN-2-YL-AMINO) -BENZAMIDE DERIVATIVES AND RELATED COMPOUND AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-28 | — | — | WO | disclosed |
| US-20050148586-A1 | Quinoxalinones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148586-A1 | Quinoxalinones | SLC5A2, GPR119, GLS2 | PYGM 271/4885DRD2 2978/4885TBXA2R 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.